Lundbeckfond Invest A/S 4
4 · Lexeo Therapeutics, Inc. · Filed Nov 9, 2023
Insider Transaction Report
Form 4
Lundbeckfond Invest A/S
10% Owner
Transactions
- Conversion
Common Stock
2023-11-07+1,321,474→ 1,321,474 total - Conversion
Common Stock
2023-11-07+287,213→ 1,608,687 total - Conversion
Series A convertible preferred stock
2023-11-07−13,999,999→ 0 total→ Common Stock (1,321,474 underlying) - Conversion
Series B convertible preferred stock
2023-11-07−2,615,533→ 0 total→ Common Stock (287,213 underlying) - Purchase
Common Stock
2023-11-07$11.00/sh+227,272$2,499,992→ 1,835,959 total
Footnotes (2)
- [F1]Upon the closing of the Issuer's initial public offering, each share of Series A convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-10.594230 basis. The shares had no expiration date.
- [F2]Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date.